Premium
Evidence for a DC‐Specific Inhibitory Mechanism that Depends on MyD88 and SIGIRR
Author(s) -
Drexler S. K.,
Wales J.,
Andreakos E.,
Kong P.,
Davis A.,
Garlanda C.,
Mantovani A.,
Hussell T.,
Feldmann M.,
Foxwell B. M. J.
Publication year - 2010
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.2010.02392.x
Subject(s) - adjuvant , vaccination , immune system , antigen , inhibitory postsynaptic potential , immunology , biology , microbiology and biotechnology , dendritic cell , innate immune system , toll like receptor , acquired immune system , neuroscience
Dendritic cells (DC) are an essential link between the innate and adaptive immune response. To become effective antigen‐presenting cells DC need to undergo maturation, during which they up‐regulate co‐stimulatory molecules and produce cytokines. There is great interest in utilizing DC in vaccination regimes. Over recent years, Toll‐like receptor (TLR) signalling has been recognized to be one of the major inducers of DC maturation. This study describes a mutant version of the TLR adaptor molecule MyD88 (termed MyD88lpr) as a novel adjuvant for vaccination regimes. MyD88lpr specifically activates DC by disrupting a DC intrinsic inhibitory mechanism, which is dependent on single immunoglobulin IL‐1R‐related. Moreover, MyD88lpr was able to induce an IgG2a‐dominated response to a co‐expressed antigen, suggesting Th1 immunity. However, when used as a vaccine adjuvant for Influenza nucleoprotein there was no significant difference in the lung viral titres during the infection. This study describes MyD88lpr as a potential adjuvant for vaccinations, which would be able to target DC specifically.